NCT04570605

Brief Summary

Pilot study for determining feasibility of home parasacral transcutaneous electrical nerve stimulation in treatment of urinary urgency and incontinence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2019

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

April 19, 2019

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 30, 2020

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

March 8, 2022

Completed
Last Updated

March 17, 2022

Status Verified

March 1, 2022

Enrollment Period

1.2 years

First QC Date

April 19, 2019

Results QC Date

January 5, 2022

Last Update Submit

March 8, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Dysfunctional Voiding Symptom Score

    At week 6 a Dysfunctional Voiding Scoring System Score. Descriptive statistics will be used to analyze these data in comparison to pre-study scores. As stated above, Dysfunctional Voiding Symptom Score is a validated clinical questionnaire designed to quantify the severity of pediatric voiding dysfunction on a scale of 0 (non-existent) to 30 (most severe).

    week 6

  • Voiding Diary and the Number of Episodes of Incontinence Per Day

    48-hour Voiding Diary and Nighttime Wetting log will be repeated and evaluated. This was added as a separate primary outcome as it is separate from the Dysfunctional Voiding Symptom Score. The voiding diary will be used to evaluate the number of episodes of incontinence per day and descriptive statistics will be used to compare this to pre-study numbers.

    week 6, week 12

Secondary Outcomes (1)

  • Secondary Outcome. Review of Adverse Events.

    Week 6 through Week 12

Study Arms (2)

Standard Urotherapy

ACTIVE COMPARATOR

Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.

Other: Standard Urotherapy

Standard Urotherapy + PTENS

EXPERIMENTAL

Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.

Device: parasacral transcutaneous electrical nerve stimulation (PTENS)Other: Standard Urotherapy

Interventions

electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.

Standard Urotherapy + PTENS

standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.

Standard UrotherapyStandard Urotherapy + PTENS

Eligibility Criteria

Age6 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Toilet trained (age 6) to age 17
  • Diagnosis of urinary dysfunction, voiding dysfunction, overactive bladder, urgency incontinence, nocturnal enuresis. (These patients may also have an element of bowel dysfunction; however, we will not include a patient who had ONLY bowel dysfunction and NOT a voiding dysfunction).

You may not qualify if:

  • Known neurologic diagnosis - such as myelomeningocele, caudal regression
  • Known seizure disorder
  • Age \< 6 or \> 17
  • Lack of follow-up within 6 months of treatment
  • Pacemaker, vagal nerve stimulator, or other implanted electrical device
  • Intolerance of electrical nerve stimulation
  • Pregnancy
  • Implanted metal hardware
  • Open sores or wounds over the sacral area
  • Currently catheterizing for bladder drainage
  • Known anatomic lower urinary tract abnormality (may be congenital or iatrogenic)
  • Bowel only voiding dysfunction (Constipation ICD-10 K59.00)
  • Non-English speaking families
  • Families with health literacy precluding completion of questionnaires and voiding diaries
  • Concurrent use of anticholinergics, alpha blockers or beta agonists for urologic treatments
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Utah/Primary Children's Pediatric Urology

Salt Lake City, Utah, 84112, United States

Location

Related Publications (2)

  • de Paula LIDS, de Oliveira LF, Cruz BP, de Oliveira DM, Miranda LM, de Moraes Ribeiro M, Duque RO, de Figueiredo AA, de Bessa J Jr, Netto JMB. Parasacral transcutaneous electrical neural stimulation (PTENS) once a week for the treatment of overactive bladder in children: A randomized controlled trial. J Pediatr Urol. 2017 Jun;13(3):263.e1-263.e6. doi: 10.1016/j.jpurol.2016.11.019. Epub 2016 Dec 21.

    PMID: 28089606BACKGROUND
  • Farhat W, Bagli DJ, Capolicchio G, O'Reilly S, Merguerian PA, Khoury A, McLorie GA. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol. 2000 Sep;164(3 Pt 2):1011-5. doi: 10.1097/00005392-200009020-00023.

    PMID: 10958730BACKGROUND

MeSH Terms

Conditions

Urinary Bladder, OveractiveUrinary Incontinence

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsUrination Disorders

Limitations and Caveats

Limitations included patients being lost to follow-up or not completing their voiding diaries or DVSS questionnaires so that the number of patients with complete information was only slightly higher than half of the total who were initially enrolled.

Results Point of Contact

Title
Glen Lau, MD
Organization
University of Utah School of Medicine

Study Officials

  • Glen A Lau, MD

    University of Utah

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
patients will be randomized to standard urotherapy or urotherapy + PTENS
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: randomized controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Surgery

Study Record Dates

First Submitted

April 19, 2019

First Posted

September 30, 2020

Study Start

April 1, 2019

Primary Completion

June 1, 2020

Study Completion

July 1, 2020

Last Updated

March 17, 2022

Results First Posted

March 8, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Individual participant data will be stored on password protected computers in the facility and collected data will be entered in a REDCap database. Individual participant data will not be shared with any individuals other than the study personnel as only these individuals will have access to the data.

Locations